ARTICLE / CLIENT ALERT
Securities Law: COVID-19 Risk Factor Disclosures in ASC Offerings
March 13, 2020
Read time: 4 min
The ongoing spread of the coronavirus disease (COVID-19) and its fallout present new risks to companies that offer securities for sale, including healthcare entities. This article highlights some COVID-19 risk factors that may be relevant to potential investors in an ambulatory surgery center (ASC) offering to investors.
Companies that offer securities for sale, including healthcare entities, typically provide a customized list of risk factors to potential investors. The ongoing spread of the coronavirus disease (COVID-19) and its fallout present new risks. Some of these risks are general, and some are specific to geographic location and healthcare providers.
Potential COVID-19 risks in connection with ambulatory surgery center (ASC) offerings to physicians are not boilerplate. The risks applicable to a specific entity must be considered from the perspective of a potential investor (who may be a physician or otherwise). Here are some COVID-19 risk factors that may be relevant in an ASC offering:
- The spread of COVID-19 poses a risk of supply chain disruption. An ASC may have to delay or cancel surgical procedures if it cannot timely obtain the implants, drugs and other surgical supplies required.
- Patients may delay or cancel surgical procedures if they fear that visiting the ASC (or related hospital or medical office building locations) might expose them to COVID-19.
- Self-quarantine or actual viral health issues may result in physician or staff shortages. Physicians and staff also may be diverted to assist with COVID-19 patients.
- Regional quarantines or shut-down of public transportation may result in delayed or cancelled surgical procedures.
- COVID-19 may be spread through encounters at the ASC.
- Lawsuits may be filed in relation to COVID-19 issues at the ASC.
- ASCs may face increased costs from continual heightened sanitation efforts.
- • COVID-19 is a public and political crisis, and unknown disruptions may occur.
- A prolonged economic downturn from the negative effects of the virus could result in job loss, loss of private insurance coverage, and reduced demand and reimbursement for ASC procedures.
- Many COVID-19 losses may not be mitigated by reducing expenses. ASC overhead (loan interest, rent, salaries) cannot be readily reduced.
- Centers for Disease Prevention and Control or state-mandated healthcare protocols may require altered operations.
- An ASC is generally not a business that can operate with employees working remotely or by video- or teleconference.
Other effects of the COVID-19 crisis, however, may provide offsetting results:
- Other relative investment returns may be weaker due to the general market decline when compared to the ASC’s return on investment.
- An ASC that is able to continue to operate normally and that is not in a quarantined area may gain cases relative to other surgical providers.
This list does not encompass all possible COVID-19 risks for investors, but it represents a range of considerations in light of the spread of the disease and the related emerging risks. The specifics of each ASC’s specialties, geography and patient demographics must be taken into account when determining risks to disclose in an offering document.

CMS COVID-19 Infection Control Guidance for Nursing, Hospice, Home Health and Dialysis Facilities
ARTICLE / CLIENT ALERT
CMS COVID-19 Infection Control Guidance for Nursing, Hospice, Home Health and Dialysis Facilities
March 13, 2020
Read time: 13 min
The COVID-19 situation is changing rapidly. We will continue to update this article as CMS revises and updates the QSO standards on infection control and prevention of COVID-19. This article was most recently updated on March 17, 2020, to reflect updates to the QSO standards for nursing facilities.
The Centers for Medicare and Medicaid Services (CMS) recently released Quality, Safety & Oversight Group (QSO) standards for infection control and prevention of Coronavirus Disease 2019 (COVID-19) in nursing facilities, hospice agencies, home health agencies and end-stage renal disease (ESRD) facilities, along with guidance on types of face masks that providers may use when responding to COVID-19 and other respiratory illnesses. CMS also clarified that all four types of care locations must maintain adequate supplies and equipment required by patients’ individualized plans of care. Given supply shortages, however, CMS will not cite facilities for having inadequate supplies for reasons outside of their control. In such an event, facilities should take action to mitigate any shortages and demonstrate that they are taking all reasonable steps to obtain necessary supplies.
Click here for an analysis of another QSO memo that addresses COVID-19-related issues specific to hospitals, critical access hospitals and EMTALA. For further information on CMS COVID-19 guidance, please visit our Coronavirus Resource Center.
Nursing Facilities
The March 9, 2020, nursing facility QSO memo focuses on several practices to limit the transmission of COVID-19 in nursing facility settings, including screening, restricting, limiting and discouraging visitors and other non-staff, non-resident personnel from non-essential visits to nursing facilities. The memo also provides instructions for when a facility should transfer or accept a resident with suspected or confirmed COVID-19 infection.
Screening and Restricting Visitation
CMS advises all nursing facilities nationwide to restrict visitation of all visitors and non-essential healthcare personnel, except for during certain compassionate care situations, such as an end-of-life situation. Decisions about end-of-life visitation should be made on a case-by-case basis and should include careful screening of the visitor (including clergy, bereavement counselors, etc.) for fever, cough, shortness of breath, sore throat or other respiratory symptoms. Symptomatic individuals or those unable to demonstrate proper use of infection control techniques should not be permitted to enter the nursing facility at any time.
When visitation is allowable, nursing facilities should make an effort to allow for safe visitation for all parties involved in ways such as:
- Providing instruction before visitors enter the nursing facility or the resident’s room on appropriate hand hygiene and the use of personal protective equipment (PPE), and increasing availability of alcohol based hand sanitizer (ABHS).
- Requiring visitors to use ABHS and PPE, particularly face masks.
- Suggesting that visitors refrain from physical contact by the practice of social distancing.
- If possible, restricting visitors to dedicated visiting areas (e.g., “clean rooms”) near the nursing facility entrance where residents can meet in a sanitized environment that is disinfected after each resident-visitor meeting.
- Advising visitors to report to the nursing facility any signs or symptoms of COVID-19 or acute illness within 14 days of visiting the facility, and to immediately notify the facility of the date they were in the nursing facility, the individuals they were in contact with, and the locations within the nursing facility they visited. Nursing facilities should immediately screen the individuals with whom contact was made and take all necessary actions based on findings.
- Taking necessary action to prevent potential transmission from non-visitor third parties, such as vendors, volunteers and other practitioners. This may include instructing vendors to leave supplies at the loading dock or requiring the donning of PPE before entering the facility. Nursing facilities can allow entry of these visitors if necessary, as long as they are following the appropriate Centers for Disease Control and Prevention (CDC) guidelines for Transmission-Based Precautions.
Deferring Visitation
Outside of allowed visitation practices (e.g., end-of-life situations), nursing facilities should advise visitors to defer visitation until further notice. Methods of discouraging visitors include:
- Emails, letters, phone calls and signage at nursing facilities recommending that visitors defer their visit for another time or for certain specific situations (e.g., end-of-life situations)
- In lieu of visits, nursing facilities can consider:
- Offering alternative means of communication for people who would otherwise visit, such as virtual communication
- Providing listserv communication to families, including advice not to visit
- Conducting regular outbound calls to keep families up to date
- Offering a phone line with a voice recording on the nursing facility’s general operating status, including whether it is safe to resume visits.
Some states are implementing nursing facility visitation restrictions that exceed CMS recommendations (e.g., banning all visitation). CMS has stated that nursing facilities will not be deemed non-compliant with CMS requirements if they follow stricter state requirements.
Transferring and Accepting Residents
If a resident is suspected of having a COVID-19 infection, nursing facilities should contact the local health department. If the infection is not serious, facilities should follow CDC infection prevention and control recommendations. Transferring residents to a hospital is not necessary unless the resident requires a higher level of care. In such an instance, the recipient hospital and emergency medical services should be alerted and instructed to wear proper PPE during the transfer.
Conversely, a nursing facility may accept a resident diagnosed with a transmissible COVID-19 infection only as long as the facility can follow CDC guidance for Transmission-Based Precautions. Absent this ability, nursing facilities should not admit the resident until the precautions are discontinued.
If an incoming resident does not have a transmissible COVID-19 infection, nursing facilities should accept the resident in accordance with their standard practice. If the resident is transferred from a hospital where COVID-19 cases were present, CMS encourages nursing facilities to dedicate a unit or wing where residents can transition into short-stay rehab or long-stay residence after demonstrating 14 days with no symptoms.
Staff, Healthcare Workers, Surveyors: Screening and Restrictions
All staff should be actively screened at the beginning of their shift for COVID-19 symptoms. If staff members are symptomatic, they should don facemasks or self-isolate at home.
Healthcare workers, including hospice care providers, EMS personnel and dialysis technicians, should be permitted to come into the nursing facility and provide care to residents as long as they meet the CDC guidelines for healthcare workers.
For now, federal and state surveyors may still enter a nursing facility if they were in contact with patients symptomatic for COVID-19 in the previous 14 days but were wearing PPE, provided the surveyor is asymptomatic. CMS and state survey agencies continue to evaluate survey practices to ensure surveyors do not pose a transmission risk when entering a nursing facility.
Resident Guidance
Residents should be actively screened for COVID-19 symptoms and reminded to practice social distancing and perform frequent hand hygiene. To support this effort, CMS advises nursing facilities to cancel all communal dining and internal and external group activities.
Key Takeaways: Nursing facilities should prepare policies and procedures for resident visitation to ensure that the facility can restrict visitors except during compassionate care situations. When visitation is permissible, facilities should provide visitors with PPE and consider limiting or discouraging in-person visits and offering alternative means of interaction. CMS expects nursing facilities to adhere to infection prevention and control recommendations when providing care and when allowing visitors to interact with residents.
Hospices (Inpatient Units, Nursing Facilities, Assisted Living, Hospitals and Home Settings)
The March 9, 2020, hospice QSO memo focuses on several practices to limit the transmission of COVID-19 in hospice and home care settings, including screening and restricting visitors and treating and transferring patients to higher-level care when appropriate.
Identifying Risk of COVID-19 in Volunteers, Visitors and Patients
As described previously in the context of nursing facilities, hospices should identify volunteers, visitors and patients at risk for having COVID-19 by asking if they meet any of the four screening criteria.
Restriction of Visitors to Hospice Inpatient Units
Medicare regulations require a hospice to focus on preventing and controlling infections. Inpatient hospice facilities may have policies regarding patients’ visitation rights and may wish to set clinical restrictions on visitation subject to patients’ rights. If the inpatient hospice services are not provided by the hospice facility itself (such as hospital-based hospice care), the third-party provider may have additional visitation restrictions to address COVID-19 transmission concerns. For more information, see McDermott’s On the Subject “This is Not a Drill: Hospital and Health System Preparedness for COVID-19.” However, if hospice services are provided in a nursing facility, hospice workers should be permitted entry upon donning appropriate PPE and following CDC guidelines for Transmission-Based Precautions.
Caring for Hospice Patients with COVID-19 Symptoms
If a patient demonstrates respiratory symptoms, hospice caregivers should notify local and state public health authorities and implement respiratory hygiene practices, including placing a face mask over the patient’s mouth and nose when coughing, and isolating the patient in a private room with the door closed. If a private room is not available, the patient should be moved to a well-ventilated space, separated from other patients by at least six feet of space. Hospice agencies should continue to adhere to Medicare PPE requirements, including provision of ABHS, tissues, no-touch trash receptacles and face masks at facility entrances.
If a patient in a hospice setting presents with COVID-19-related symptoms, hospice facilities should consult with the patient, the patient’s representative, and state and local public health authorities before deciding whether to administer a diagnostic test versus presuming a positive COVID-19 diagnosis. Patients in home hospice settings should be hospitalized or transferred to an inpatient hospice unit only if their symptoms are exacerbated by a COVID-19 infection that cannot be managed in the home setting.
Key Takeaways: Hospice facilities and providers should consider a patient’s unique healthcare needs and the severity of COVID-19-related symptoms when considering whether to allow visitors to inpatient hospice settings and whether to transfer hospice patients in home settings to an inpatient facility.
Home Health Agencies
The March 10, 2020, home health agency QSO memo focuses on several practices to limit the transmission of COVID-19 in home care settings, including educating family members and treating and transferring patients to higher-level care when appropriate.
Identifying Risk of COVID-19 in Patients
As described above in the context of nursing facilities, home health agencies should identify patients at risk for COVID-19 before or immediately upon arrival at the home by asking patients if they meet any of the four screening criteria.
Caring for Home Health Agency Patients with COVID-19 Symptoms
If a patient demonstrates respiratory symptoms, healthcare professionals should notify the home health agency clinical manager and local and state public health authorities and implement respiratory hygiene practices when caring for the patient. Home health agencies should advise the patient to stay home except to get medical care and to limit contact with other people and animals as much as possible. Home health agencies should advise family members on for preventing the spread of COVID-19 in the home (e.g., hand-washing, monitoring symptoms, regularly cleaning high-touch surfaces, not sharing personal items), including prevention and control recommendations.
Home care staff and other individuals in the home should continue to adhere to Medicare PPE requirements, including the use of ABHS, gowns and face masks. Healthcare professionals and home care staff should be limited to essential personnel only; should don PPE outside of the home prior to entry or, at a minimum, put on face protection prior to entering the home; and should discard used PPE in an external trash receptacle prior to departing the home health service location. Healthcare professionals are encouraged to perform hand hygiene using ABHS prior to removing face protection and again after disposing of PPE.
If home health agencies anticipate providing care to patients confirmed or presumed to have COVID-19 along with respiratory or gastrointestinal symptoms, those agencies should refer to the Interim Guidance for Public Health Personnel Evaluating Persons under Investigation (PUIs) and Asymptomatic Close Contacts of Confirmed Cases at Their Home or Non-Home Residential Settings.
Transfer of Patients
Although COVID-19 patients with mild symptoms may be managed at home, the decision to remain in the home should take into account the patient’s ability to adhere to isolation recommendations along with the potential risk of secondary transmission to household members with immunocompromising conditions. Hospitalization is not required if CDC home care monitoring guidelines can be followed and the patient does not require a higher level of care. If a hospital transfer becomes necessary, the recipient hospital and emergency medical services should be given all necessary medical information and instructed to wear proper PPE during the transfer.
Key Takeaways: Home health providers should wear a face mask prior to entering the home of a patient with COVID-19 symptoms, practice respiratory precautions when providing care, and remove the face mask only after exiting the home. Patients with COVID-19 generally should remain at home until symptoms abate unless a higher level of care is needed. In such case, personnel transporting or receiving the patient should be notified about the importance of wearing appropriate PPE.
Dialysis Facilities
The March 10, 2020, dialysis facility QSO memo focuses on several practices to limit the transmission of COVID-19 in dialysis facility settings through screening patients and staff, isolating patients with suspected or confirmed COVID-19 infections, and transferring patients to alternative dialysis locations.
Identifying Risk of COVID-19 in Patients and Staff
Dialysis facilities are encouraged to screen patients, staff and visitors for COVID-19 symptoms using the four criteria listed previously. Patients who present with signs and symptoms of respiratory infections should be identified prior to entering the dialysis treatment area and should be required to wear a face mask at check-in and until they leave the facility. Dialysis facilities are also encouraged to post signage at the facility entrance instructing patients to notify staff if they have a fever or respiratory infection symptoms so that appropriate precautions may be exercised. Staff who demonstrate signs and symptoms of respiratory infection should not report to work, or if symptoms arise at work, they should immediately stop working, don a face mask, self-quarantine at home, and inform the dialysis facility administrator of any patients or staff with whom they came into contact.
Caring for Patients with COVID-19 Symptoms
CMS recognizes that patients will continue to need dialysis treatment during the symptomatic stage of a COVID-19 infection, so dialysis facilities are encouraged to provide masks to symptomatic patients and to have space in waiting areas to segregate ill patients from other patients by at least six feet. If possible, dialysis treatment of symptomatic patients should occur in a separate room with the door closed or otherwise away from the main flow of traffic, and at least six feet from other patient stations. Facilities should continue to follow infection control requirements, including hand hygiene, PPE, isolation, routine cleaning and disinfection procedures.
For patients who receive at-home dialysis treatments, CMS emphasizes that monthly monitoring in onsite locations should continue in accordance with these precautions.
Transferring Patients to Alternative Sites
Dialysis facilities should consider transferring patients to another treatment site if the facility cannot fully implement the recommended precautions or if the patient requires care that the facility is unable to provide. Transport personnel and the receiving facility should be notified in advance of the patient’s healthcare needs, and the patient should wear a face mask and remain separated from other patients while awaiting transfer.
Key Takeaways: Dialysis services remain necessary for patients infected with COVID-19 or demonstrating signs and symptoms of respiratory infections. Dialysis facilities should provide masks and segregate symptomatic patients by at least six feet if a private room or separate wing is not available.
Conclusion
CMS has provided helpful advice to healthcare providers in non-hospital settings regarding COVID-19-related infection control practices. Limiting, restricting and discouraging visitors in accordance with facilities’ policies and procedures will go a long way toward reducing otherwise avoidable transmissions while allowing caregivers to focus on patients’ individualized needs.

CMS Releases Updated Guidance on EMTALA Requirements and COVID-19 Implications
ARTICLE / CLIENT ALERT
CMS Releases Updated Guidance on EMTALA Requirements and COVID-19 Implications
March 13, 2020
Read time: 10 min
In response to the spread of COVID-19 infections and questions from the provider community, the Centers for Medicare and Medicaid Services (CMS) Quality, Safety and Oversight Group (QSO) issued a series of three memoranda providing updated guidance to healthcare facilities on March 9, 2020.
This alert focuses on QSO-20-15 Hospital/CAH/EMTALA, entitled Emergency Medical Treatment and Labor Act (EMTALA) Requirements and Implication Related to Coronavirus Disease 2019 (COVID-19). Click here for an analysis of the other QSO memos that address issues specific to nursing homes, hospice and home health agencies, and dialysis providers. For more information on CMS COVID-19 guidance, visit our Coronavirus Resource Center.
Background and Current Crisis
EMTALA was first established in the 1980s as an “anti-dumping” law to dissuade hospitals from refusing to care for uninsured patients seeking emergency care. It requires Medicare-participating hospitals and critical access hospitals (collectively referred to herein as “hospitals”) with emergency departments (EDs) to minimally provide the following:
- A medical screening examination (MSE) to every individual who presents to the ED for examination or treatment of a medical condition to determine whether the individual has an emergency medical condition (EMC) (for EMTALA purposes, an EMC exists when the individual has “acute symptoms of sufficient severity such that the absence of immediate medical attention could reasonably be expected to result in serious impairment or dysfunction”)
- Necessary stabilizing treatment for individuals with EMCs within the hospital’s capability and capacity
- Transfers of individuals with EMCs to other hospitals, when appropriate and transferred in a manner that meets EMTALA requirements.
These requirements describe the basic foundation of EMTALA. The statute, regulations and their interpretation by CMS and courts over the years has resulted in additional complexity that must also be considered. For example, EMTALA requires that hospitals with specialized capabilities accept patients with EMCs in transfers as long as the recipient hospital has the capabilities and capacity to treat those patients, even if that hospital does not have an ED. EMTALA also limits hospitals as to how and where MSEs are conducted.
Hospitals have expressed concern regarding their ability to comply with EMTALA in the face of increasing ED visits from individuals with potential coronavirus exposure or full-blown disease. QSO-20-15 provides specific compliance guidance and identifies steps hospitals can take in the key areas of transfers, screening, patient access/constructive dumping and EMTALA waivers. Read on for a summary of the guidance provided in QSO-20-15 and key takeaways for hospitals to consider as they work through their EMTALA obligations during the COVID-19 crisis.
Patient Transfers
QSO-20-15 confirms that, regardless of a patient’s COVID-19 status, hospitals with the capacity and specialized capabilities necessary to provide stabilizing treatment are required to accept appropriate transfers from hospitals that do not have the necessary capabilities.
This requirement is dependent upon (1) coordination with state or local public health officials on placement of patients, and (2) at the time standards of practice to treat patients with COVID-19 (which in certain circumstances could potentially support standards such as clustering patients in specific facilities or locations).
In assessing a violation of EMTALA regarding acceptance of transfers under these circumstances, CMS notes that it would “take into account the CDC’s [Center for Disease Control and Prevention’s] recommendations at the time of the event in question in assessing whether a hospital has the requisite capabilities and capacity.” Specific to “capacity,” QSO-20-15 states that the presence or absence of negative pressure patient treatment rooms (also known as airborne isolation rooms) is not dispositive in determining capacity or capability when in some cases COVID-19 patients can be safely treated in a private patient room.
Key Takeaways: Barring a state or local public health pronouncement on patient placement, or specific standards adopted for COVID-19 treatment, all hospitals with the capability and capacity to care for patients with presumptive or confirmed COVID-19 based on current CDC treatment guidance must be prepared to accept appropriate transfers, regardless of the size of the facility or the presence of available negative pressure patient treatment rooms. CMS expects that all hospitals are capable of maintaining isolation requirements for COVID-19.
Screening and MSEs
CMS recognizes a range of potential screening sites for COVID-19 infection and other “influenza-like-illnesses” (ILIs), including alternative sites on a hospital’s campus, off-campus hospital controlled sites and community-based screening clinics not under hospital control.
On-Campus Screening Sites
On-campus screening sites may be located outside of the ED as long as (1) patients are consistently logged by the hospital as presenting for care and (2) any direction of patients to the screening site is made by qualified personnel (such as a registered nurse) to ensure that patients that require immediate care in the ED are directed appropriately.
Screening sites may be outside of the ED and may conduct MSEs tailored to the patient’s presenting signs and symptoms, as long as the site is able to determine whether an EMC is present. All sites must be part of the certified hospital, or added as a new practice location under the hospital’s provider enrollment, and approved from a state licensure perspective, which could be complicated should temporary structures or tents be used.
In these locations, MSEs must be conducted by “qualified medical personnel” as defined by EMTALA, and stabilizing treatment or an appropriate transfer must be provided to individuals found to have an EMC (including transfer to other on-campus locations for care). CMS expects hospitals to have policies and procedures in place on alternative care sites.
Off-Campus Screening Sites Under Hospital Control
Off-campus, “hospital controlled” screening sites may be used to screen patients with ILIs, and hospitals and community agencies or officials may promote the option to go to such sites for this purpose, as long as the hospital does not route patients that have presented to its ED for similar screening or care to those sites to receive an MSE. Medical personnel with appropriate training to evaluate individuals with ILIs may staff these locations.
Managing public perception with regard to these sites is important. CMS has specified that off-campus locations should not be held out as a place that provides care for EMCs in general on an unscheduled, urgent basis. Rather, these locations should be identified as ILI screening centers.
CMS has not specifically articulated what it means for a screening site to be “controlled” by a hospital in this context. It has noted that if the off-campus location is not a dedicated ED as defined by EMTALA, EMTALA obligations do not apply to the care rendered at the location, but if the site is under the “control” of the hospital, the CMS Conditions of Participation for Hospitals do apply. As a result, any individuals screened for ILI who require additional medical care on an emergent basis must be transferred to an acute care hospital for further care. This suggests that “control” may be synonymous with provider-based status or other indicia that a location is part of a hospital, but that is not clear.
Community-Based Screening Sites Outside of Hospital Control
Screening sites established by community organizations or agencies that are outside the control of hospitals are not subject to EMTALA requirements. Hospitals and community agencies or officials may promote the option to receive ILI screening at these locations, as long as the hospital does not route patients that have presented to its ED for similar screening or care to those sites to receive an MSE.
CMS encourages community-based sites to use medical personnel trained in screening for ILIs and to have transport arrangements in place with EMS to ensure safe transport of individuals that need additional medical attention to appropriate care locations.
Key Takeaways: While CMS has identified three categories of screening locations that may be used to screen for ILIs, including COVID-19, it has clarified that these alternate screening sites cannot be used as a landing pad for individuals who present to the hospital ED requesting care. Up-front consideration of the nature of an alternate site and the regulatory requirements that attach to its use should be part of planning and implementation of screening at such sites.
Patient Access/Constructive Dumping
QSO-20-15 reiterates that it is a violation of EMTALA for hospitals with EDs to use signage that “presents barriers to individuals who are suspected of having COVID-19 from coming to or receiving an MSE at the hospital ED.”
It is important to distinguish between signage that directs patients to locations on hospital property for an MSE (i.e., to an on-campus screening site, as described above, or to a specific part of the ED where all individuals presenting with ILIs will be screened) and signage that risks interpretation as “constructive dumping” because it causes a patient to reconsider receiving care and to leave before an MSE can be performed and/or stabilizing treatment rendered. Hospitals that have established off-campus ILI screening sites may make ED patients aware of those sites, but may not direct patients who present to the ED to those sites for screening or care. Permitting a patient’s use of her own car as a waiting location outside the ED does not relieve the hospital of the obligation to monitor that patient and her clinical condition while the patient awaits further evaluation.
Key Takeaways: Hospital counsel should be involved in decision-making around ED signage specific to COVID-19 to avoid inadvertent miscommunication to patients and third parties regarding screening processes and willingness to provide care to patients regardless of COVID-19 status.
EMTALA Waivers
QSO-20-15 further references EMTALA “waivers” that would permit hospitals to direct or relocate patients who present to the hospital ED and request an MSE to alternative, off-campus sites consistent with state or local emergency or pandemic preparedness plans, or to transfer unstable patients as long the transfer is required by the circumstances presented by the emergency. As mentioned in our prior On the Subject, these waivers are not available until:
- The president declares an emergency or disaster under the Stafford Act or National Emergencies Act
- The secretary of HHS declares a public health emergency
- The secretary of HHS invokes the waiver authority with 48 hours advance notice to Congress
- The waiver ultimately granted provides relief from EMTALA requirements and the hospital at issue qualifies for the waiver (which is based on a facts and circumstances analysis).
Key Takeaways: While EMTALA waivers are not presently available (as of the date of this article, there has not been a presidential declaration of emergency or disaster), hospitals should remain aware of their potential application in the future, should the requirements for their implementation be met.
Conclusion
CMS has made it clear that hospitals cannot simply refuse to screen and treat patients with suspected or confirmed COVID-19. Such refusal risks violating EMTALA, regardless of a patient’s signs and symptoms on arrival or eventual diagnosis.
Survey activity in relation to alleged EMTALA violations is largely complaint-based. While CMS announced a pause in most non-emergent survey activity, hospitals should be prepared for follow-up on alleged EMTALA violations inasmuch as they affect patient safety, are determined to cause immediate jeopardy, or are revived once the COVID-19 crisis has passed (i.e., it is possible that survey activity could occur long after an alleged violation occurs as CMS works through a backlog of complaints that were not fully reviewed during the time when non-emergent surveys were on hold).
While the potential for a federal waiver from compliance with certain of EMTALA’s regulatory requirements exists, currently such waivers are not available. If waivers are made available, hospitals should evaluate their applicability to their operations and determine whether additional steps are necessary to secure the protection of the waiver.

Déjà Vu – SCOTUS to Review Validity of Affordable Care Act
ARTICLE / CLIENT ALERT
Déjà Vu – SCOTUS to Review Validity of Affordable Care Act
March 13, 2020
Read time: 3 min
The Supreme Court ruled in 2012 that the Affordable Care Act (ACA) was constitutional pursuant to Congress’ power to levy taxes. Since that decision, Congress reduced the ACA’s individual mandate’s tax penalty to $0. With the individual mandate effectively repealed, a divided panel of the Fifth Circuit held all the provisions of ACA unconstitutional. Recently, the Supreme Court agreed to review the Fifth Circuit’s decision.
In 2012, the Supreme Court determined that the ACA’s mandate requiring individuals to maintain health insurance was constitutional. The Court’s decision focused on the penalty the ACA imposed on those who did not have insurance, which the Court found to be within Congress’ taxing power. Congressional Republicans then reduced the tax penalty to $0, launching new lawsuits attacking the constitutionality of the ACA. One such suit, brought by Republican state officials in Texas, reached the Fifth Circuit. In a 2-1 decision, the Fifth Circuit found the penalty-free mandate unconstitutional, but did not decide the larger question of the constitutionality of the rest of the ACA without the individual mandate. The Fifth Circuit remanded the case to the district court to consider whether the mandate could be severed from the rest of the Act. Recently, the US Supreme Court agreed to review the Fifth Circuit’s decision, and arguments are likely to be set for this fall.
McDermott Thoughts:
The Fifth Circuit’s divided decision, and the Supreme Court’s agreeing to review that decision, further emphasizes healthcare as a hot topic in the upcoming elections. Questions of the ACA’s constitutionality have implications on individuals, businesses, the health-insurance industry and the economy generally.
In reviewing this case, the justices may decide the fate of every provision of the ACA. In addition to the mandate that most people carry health insurance, the ACA barred insurers from denying coverage—or charging more—to people with existing health conditions. It also allowed young adults to stay on their parents’ plans until they turned 26 and expanded the availability of Medicaid coverage for limited-income Americans. The ACA contains hundreds of other provisions, including ones that require contraception coverage and federally recommended vaccines to be covered at no cost, and that mandate nutritional labeling on restaurant menus and vending machines. Repeal of the ACA will have far-reaching ramifications.
Since the Supreme Court’s 2012 decision upholding the ACA, the Supreme Court has changed, although Chief Justice John Roberts famously broke the tie in 2012 when he voted to uphold the Act. We expect that the Supreme Court will be flooded with amicus briefs by interested organizations and industries, and it remains to be seen whether the Court will strike the ACA or, as it did before, find reasoning to uphold its constitutionality.

COVID-19 – Contingency Planning Checklist for Private Equity Portfolio Companies
ARTICLE / CLIENT ALERT
COVID-19 – Contingency Planning Checklist for Private Equity Portfolio Companies
March 13, 2020
Read time: 15 min
Following the wider outbreak of the coronavirus (COVID-19) around the world, radical—and sometimes controversial—actions have been and are further expected to be taken by national, federal and local governments and authorities in affected countries. Given the scope of these actions, along with widespread impacts of the crisis on employment, supply chains, pending M&A activity, capital markets and more, boards are urged to take action now to ensure the health of contingency plans, mitigate risks, tackle immediate priorities and ensure business continuity and stability.
This high-level checklist can help corporates and portfolio companies of private equity funds navigate current uncertainties related to COVID-19.
Following the wider outbreak of the coronavirus (COVID-19) around the world, radical actions have been and are further expected to be taken by national and federal governments as well as federal and local authorities in affected countries. The primary objective of such actions, some of which are controversial and the subject of much discussion among scientists, politicians, the media and the public, is to alleviate the rapid speed at which the virus spreads so to ensure that already overburdened national health systems can cope with the anticipated influx of COVID-19 cases. These actions, combined with inevitable employee absences, are expected to significantly affect the way in which companies operate their businesses and manage their risks in the short- to mid-term.
The potential scope and term of many of these actions are largely unknown, will vary from country to country and between federal states and regions, and are not yet understood in full. The COVID-19 crisis also provides significant challenges to pending M&A, capital markets, financing and restructuring transactions. Last but not least, new investment opportunities will arise as a result of the crisis.
Boards need to take action now in order to check the health of contingency plans, mitigate risks, tackle immediate priorities and ensure business continuity and financial stability. To assist in this process, McDermott Will & Emery* (McDermott) has put together this high-level checklist designed to support companies in navigating current uncertainties. This checklist has been prepared from a general legal and best-practice perspective for corporates and portfolio companies of private equity funds in the United States, United Kingdom, France and Germany. (For recent developments in Italy, please see our client update, “COVID-19 – recent legal developments in Italy and practical implications.”) To address any questions in connection with COVID-19, particularly in this changing environment, an agile approach and tailored responses will be required that take into consideration applicable laws, policies and guidelines in the relevant countries as well as recent developments.
The outbreak of COVID-19 is moving quickly, and some of the considerations in this checklist may fall rapidly out of date. This checklist reflects our considerations as of 13 March 2020 and has not been updated since then. This checklist is for general information purposes only and should not be construed as legal advice or any other advice on any specific facts or circumstances. It cannot serve as or replace specific advice for individual COVID-19 related questions and matters and no one should act or refrain from acting based upon any information herein without seeking professional legal advice. For specific legal advice on COVID-19 please contact your usual McDermott contacts and experts.
I. General Crisis Management – Cross-Functional COVID-19 Task Force
Establish a dedicated task force reporting to the CEO or board with representatives from all major business lines and central functions (including HR, procurement, IT, finance, treasury, regulatory, communication/investor relations and legal) and covering all countries and regions material for the business. Assign responsibility for:
- Assessing, monitoring and managing the development and impact of COVID-19, including compliance with the requirements and guidance issued by government bodies and local authorities.
- Contingency and response planning, including business continuity, work force management and industry-side and business area-specific risk mitigation and orchestration of activation and implementation.
- Communications, including internal and external communication of safety measures and response plans with employees, customers, suppliers, lenders, regulators/government bodies and other key stakeholders in the business.
II. Employment/Workforce Considerations – Protect your Employees
- Check, monitor and comply with WHO guidelines and the requirements and guidance issued by government bodies and local authorities in connection with the health and safety of employees, including the Centers for Disease Control and Prevention in the United States (CDC).
- Check, monitor and comply with notification obligations required by government bodies (including local entities) and make all appropriate containment, isolation or quarantine arrangements.
- Review and be aware of the obligations and rights of the company under employment agreements and collective bargaining agreements, and under employment legislation, including applicable privacy rights and obligations.
- Introduce new policies to prevent the spread of COVID-19 (and consider updating works council and collective bargaining agreements where appropriate) and communicate clearly with employees:
a) Provide employees with the necessary equipment and technology to work remotely where appropriate (e.g., laptops).
b) Instruct (to the extent permissible under applicable laws in your country) and/or ask employees to take their work equipment and technology home at the end of every working day.
c) Consider introducing temporary flexible working policies.
d) Consider having fever thermometers on hand for voluntary self-checks of employees or to offer/conduct health and fever checks for employees, to the extent permitted by applicable law.
e) Consider instructing (to the extent permissible under applicable laws in your country) and/or asking employees to stay at home and not to come to the office/ workplace even if they show only mild cold symptoms.
f) Consider whether employees should be instructed (to the extent permissible under applicable laws in your country) and/or allow employees to stay at home and not to come to the office/ workplace if family or household members have been diagnosed with COVID-19 or are otherwise in self-isolation.
g) Limit or prohibit business travel, particularly to high-risk areas, and discourage face-to-face meetings. Instead, introduce ‘virtual’ meeting solutions such as videoconferences. Consider self-quarantine measures for employees returning from non-business travel.
h) Require employees to notify the company of possible exposure to COVID-19 (including following travel to high-risk areas), subject to privacy laws.
i) Provide training, equipment and support to prevent the spread of COVID-19. - Put in place arrangements to perform business-critical functions, if a material part of staff is absent (e.g., relocation of staff from high-risk areas).
- Consider back-up arrangements and alternates for key personnel/functions.
- To the extent available in your country, consider applying for short-time work compensation (e.g., so called Kurzarbeitgeld in Germany) and/or compensation from public authorities in the event of quarantine measures being imposed on employees.
- Ensure strategies, policies, measures and communications (i) are proportionate to the health and safety objective, (ii) sustainable over time and (iii) comply with anti-discrimination and privacy laws.
III. Regulatory Matters
- Prepare, coordinate and communicate with relevant authorities at the appropriate time to address (potential) containment, (temporary) shutdown of operations and/or sites, quarantine or changes to the business operations, if any. If need be, inform authorities regarding lead times for reduction of critical operational activities and levels.
- Put in place arrangements to avoid or mitigate shutdowns, relocate to and/or perform operations or critical functions in low-risk areas, in case a material part of operations is located in (potential) high-risk areas and/or subject to containment restrictions, (temporary) shut-downs or quarantine (e.g., relocation of operations from high-risk areas).
- Update emergency and business continuity plans to have documentation available when coordinating and discussing containment, shutdown of operations and/or sites and quarantine with relevant authorities.
- Review whether any containment, (temporary) shutdown or change to the business operations triggers an obligation to notify the regulatory authorities. Identify competent authorities and check back with responsible personnel on your side.
- Consider delayed responses and approvals from regulatory authorities from staff shortages as a result of remote working, travel restrictions, etc., and implications for pending measures.
- Regularly check (extended) travel restrictions issued by national or federal authorities.
- Regularly check extended customs clearance and/or expert control restrictions.
- Regularly check for industry- and sector-specific developments and regulatory updates—in particular, in the healthcare and life sciences industries.
IV. Commercial Agreements/Supply Chain Disruptions
- Identify and mitigate any potential supply chain disruptions caused by containment zones, factory closures, travel restrictions or employee absences due to illness or quarantine.
- Consider short-term changes to supply chain and logistics models to avoid disruption (e.g., qualify alternative source replacement suppliers or vendors and consider production alternatives).
- Evaluate and consider impacts on vendors’ ability to deliver and customers’ ability to pay on time.
- Review contractual arrangements to identify the company’s rights and obligations arising in respect of delays in production or failure to fulfill outstanding orders (e.g., events of default, cross-default, notice and termination requirements, and applicability of force majeure) and any related consequences of a breach, including dispute resolution provisions and potential applicability of the United Nations Convention on Contracts for the International Sale of Goods (CISG).
- Review adequacy of force majeure terms of material contracts.
- Introduce alternative communication channels with customers and suppliers in anticipation of and while travel restrictions remain in effect.
- Consider short-term marketing and sales responses to demand shocks.
V. Corporate and Capital Markets
- Coronavirus/COVID-19 and M&A:
a) Consider impacts on transactions: Expect delay, including issues arising from enhanced due diligence, reduced availability of acquisition financing, and warranties and exclusions from indemnities (W&I) insurance, and a potential slowdown/ retraction of auction sale processes, especially in affected sectors.
b) Conduct enhanced due diligence with a risk-based approach for sectors directly affected (e.g., retail, travel and leisure industry) or indirectly affected (e.g., operations, supply chains, customers in high-risk or containment areas).
c) Review valuation questions and measures to bridge the gap in affected sectors (e.g., earn-out, deferred or staggered consideration, vendor loan, reinvestment rollover).
d) Expect changes to customary risk allocation provisions in transaction agreements (e.g., market/business MAC, material adverse event (MAE), warranty bring-down, (extended) long-stop dates, break-up fees, reverse break-up fees, representations and warranties relating to COVID-19).
e) Address uncertainty in leverage financing, in particular business and market MAC clauses in financing commitment letters and other provisions affecting certain fund requirements.
f) For pending transactions, review termination rights and consequences in case of material adverse change; consider the impacts of a delayed regulatory approval process and implications for closing. - Coronavirus/COVID-19 – General Corporate and Capital Markets:
a) Consider the need to postpone or to make alternative arrangements for board and shareholder meetings.
b) Consider the need to postpone intended fundraising on capital markets until volatility subsides and identify alternative sources of funds.
c) Assess the impact of lower or volatile market prices on transactions, including the valuation of consideration shares, the pricing of warrants and regulatory obligations linked to the value of transactions relative to market capitalization.
d) Identify potential mark-to-market obligations, margin calls, etc., in respect of financial instruments and make plans for meeting them.
e) Review potential effects on ongoing prospectus approval procedures with regulators; it may be necessary to rewrite or supplement, in particular, the risk factors included in the prospectus/offering memorandum.
f) Identify whether European issuers may be obliged to publish ad hoc announcements pursuant to Article 17 (1) of the European Market Abuse Regulation due to the effects of the COVID-19. The US Securities and Exchange Commission has advised companies subject to US reporting obligations to provide investors with disclosures regarding their assessment of, and plans for addressing, material risks to their business and operations resulting from the coronavirus and to ensure that coronavirus-related disclosures are disseminated broadly and updated to the extent that information becomes materially inaccurate. Similar obligations may exist under rules and regulations in other jurisdictions. For example, material operations located in containment zones and the disruption of the production or the supply chain because of the COVID-19 outbreak may oblige issuers of financial instruments to notify the public on an ad-hoc basis.
g) Issuers typically release their annual reports at this time of the year (provided the business year is identical with the calendar year). COVID-19 poses a challenge in particular in regards to the risk report and the prognosis / forecast report and needs to be carefully worded in order not to expose the issuer to liability risks. The same applies to quarterly and half-yearly financial reports. - Identify and assess new investment opportunities arising in the crisis.
VI. Financing
- Ensure sufficient liquidity is available to weather the storm (and implement proactive cash management measures).
- Regularly analyze the impact of COVID-19 (in particular, interruption of normal business activities, supply chain disruption, decreased sales, and extended containment and travel restrictions) affecting cash flows and EBITDA (i.e., financial stress testing).
- Consider updating/adjusting business plans and budgets to address changes in operations and potential defaults resulting from government actions, including containment zones.
- Review and monitor obligations under existing financing arrangements to:
a) Comply with ad-hoc obligations to notify the lender(s) about issues that could adversely affect the financial condition and/or operations of your business.
b) Verify compliance with agreed general undertakings and representation and warranties.
c) Verify compliance with agreed financial covenants (in particular, on the next testing dates) and assess (if needed) availability of additional funds from shareholders to equity cure potential breaches of financial covenants.
d) Engage with lenders and other stakeholders to encourage proactive discussions with a view to (temporarily) waive and/or suspend events of default (including cross-defaults) and other applicable restrictive provisions. - Check if you are eligible for any subsidies or other financial support from national authorities with regard to financial losses incurred due to COVID-19 (e.g., short- time work compensation allowance schemes).
VII. Restructuring
- Monitor insolvency filing obligations and fiduciary duties in the zone of insolvency, and avoid liabilities due to an illiquidity or an over-indebtedness. (With respect to over-indebtedness, please note: the over-indebtedness may kick in much earlier than the illiquidity under German insolvency law in case of a negative going concern prognosis for the current and next fiscal year!)
- Review (potential) restructuring needs and explore measures to cope with these by way of a preventive and/or insolvent restructuring.
- Review (potential) external financing needs, available financing (re-)sources (e.g., existing lenders, alternative lenders, factoring, sale and lease back) and anticipate their potential requirements (e.g., restructuring opinion for existing lenders).
- Review intra-group financings and related risks for each group company as managers of cash flow-positive subsidiaries may have to refrain from feeding a cash pool on an unsecured basis.
- Keep credit insurers informed in order to prevent them from cutting their support and to ensure early awareness of developments at that end.
- Contact governmental authorities in order to apply for/obtain potential emergency support (i.e., subsidies, short-time allowance) in due course.
- Prepare for a prolonged period of uncertainty as the risk of global recession heightens.
VIII. Insurance
- Review insurance policies to assess potential recoveries for any business disruption.
- Ensure notifications to insurers are made as required under existing policies.
- Review and clarify needs for additional insurance coverage as the situation develops.
IX. Data Privacy
- Identify potential data privacy/leakage risks due to loss of business-critical functions.
- Update technical and organizational measures to ensure that personal data related to notification requirements (especially health data regarding employees or customers) is also covered and protected.
- Do not collect more data than necessary, even in view of COVID-19. In particular, consider carefully whether you really need to know who exactly in the employee’s household is affected and whether they are ill or just self-isolating.
- Check/review company policies regarding remote working and other work arrangements. Consider additional training for employees who do not normally work remotely.
- Evaluate the use, transfer and storage of new data gathered from individuals (e.g., customers, suppliers and employees) in respect of enhanced risks, including diary management/travel plans, emergency contracts and health data.
- Stress test robustness of IT systems and cybersecurity controls in anticipation of allowing/requiring employees to work from home.
- Evaluate involvement of data privacy authorities.
X. Sector-Specific Considerations
- Healthcare
a) Review and update policies for healthcare workers in clinical and non-clinical settings to take into account national and local government advice for healthcare workers.
b) Review and update emergency and disaster planning policies, particularly in the context of clinical settings.
c) Review and update relevant policies, including infection control, decontamination, transfer and management of patients, and care of the deceased.
d) Assess business impacts on health providers: review contracts (with payers, commissioners and supply chain) in respect of required notifications on force majeure and suspension of health services.
e) Review and plan for changes in business demand, particularly in non-urgent face-to-face care (including options for remote care) and likely increases in demand for diagnostics, intensive care support and related services. - Life Sciences
a) Review and manage supply chain issues and guidance in respect of demand and supply of medicines and devices.
b) Review and comply with antitrust and related guidance on the pricing of in demand drugs and devices.
c) Maintain ongoing review of regulatory guidance on acceleration of clinical trials and clinical trial support services.
McDermott is advising clients on a wide range of COVID-19 related matters in various sectors, including healthcare and life sciences. For further information, newsletters, alerts and updates on COVID-19-related matters, please refer to the McDermott Coronavirus Resource Center.
This material is for general information purposes only and should not be construed as legal advice or any other advice on any specific facts or circumstances. No one should act or refrain from acting based upon any information herein without seeking professional legal advice. McDermott Will & Emery* (McDermott) makes no warranties, representations, or claims of any kind concerning the content herein. McDermott and the contributing presenters or authors expressly disclaim all liability to any person in respect of the consequences of anything done or not done in reliance upon the use of contents included herein. *For a complete list of McDermott entities visit mwe.com/legalnotices.

Short-Selling — Short-Selling Bans Instituted Across Europe and Asia
ARTICLE / CLIENT ALERT
Short-Selling — Short-Selling Bans Instituted Across Europe and Asia
13 March 2020
Read time: 2 min
All fund managers that trade in the equity markets should be aware that many exchanges and countries have implemented short-selling bans overnight. As of the opening of trading Friday, 13 March, this includes Italy, Spain, the United Kingdom (but limited to the names subject to the Spanish and Italian bans), Turkey and South Korea. There are no public statements at this time on whether there will be any actions in the U.S. markets.
We are assessing the situation, but the situation is fluid. Before initiating any short sales or increasing any existing short positions (including on swap, via ADRs, or country-focused indices or baskets), fund managers should assess the situation in the relevant market at the time of the transaction.
Authored by Brian T. Daly and Anna Maleva-Otto.
If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.
This communication is issued by Schulte Roth & Zabel LLP and Schulte Roth & Zabel International LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP and Schulte Roth & Zabel International LLP.
All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.
FDA Update: COVID-19 Testing, Vaccine Development and Other Impacts
ARTICLE / CLIENT ALERT
FDA Update: COVID-19 Testing, Vaccine Development and Other Impacts
March 12, 2020
Read time: 10 min
In response to the United States’ rapidly evolving public health situation, the US Food and Drug Administration (FDA) recently released guidance on high-complexity in vitro diagnostic (IVD) tests for COVID-19. This article provides a high-level overview of regulatory standards for expedited pathways available for COVID-19 vaccine development, and offers an update on COVID-19’s impact on the medical product supply chain and FDA’s proposed mitigations.
Laboratory-Developed Test Guidance for COVID-19
On February 29, 2020, FDA issued a Policy for Diagnostics Testing in Laboratories Certified to Perform High Complexity Testing under CLIA prior to Emergency Use Authorization for Coronavirus Disease-2019 during the Public Health Emergency: Immediately in Effect Guidance for Clinical Laboratories and Food and Drug Administration Staff. Under this guidance, labs that are certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) to perform high-complexity testing may offer in vitro diagnostic tests for the detection or diagnosis of COVID-19 while pursuing an Emergency Use Authorization (EUA). An EUA allows continued use of an unapproved product, such as a diagnostic test or vaccine, in response to a public health emergency. The guidance provides minimum validation testing requirements for these diagnostic tests, including specific guidance for limit of detection, cross-reactivity, inclusivity and clinical evaluation.
FDA requests that developers notify the agency once their tests are validated and submit a completed EUA request within 15 business days of validation. While a lab awaits EUA for its test, FDA recommends that the lab send the first five negative and the first five positive specimens for testing using another EUA-authorized assay as an independent check on its validity. FDA is also working with other CLIA-certified laboratories to deploy COVID-19 tests.
While FDA Commissioner Hahn stated that the guidance does not change FDA’s standards for issuing EUAs, the guidance is unusual in explicitly announcing that FDA will not take enforcement action on diagnostic tests that are offered as laboratory-developed tests (LDTs). Notably, FDA issued warning letters to several laboratories that offered testing for Zika virus without an EUA during the 2018–2019 outbreak. FDA’s change in course for COVID-19 reflects the difficulty of identifying and isolating coronavirus infections and public laboratories’ potentially limited capability to deploy the quantities of tests currently required.
Vaccine Development
In conjunction with the demand for reliable diagnostic tests for COVID-19, stakeholders continue to ask when a vaccine for COVID-19 will become available. Similar to diagnostic tests, FDA may grant an EUA for a COVID-19 vaccine. FDA has various expedited programs that may speed up its review of vaccines in a public health emergency. However, even with the availability of an EUA or an expedited program, developers must meet threshold requirements to demonstrate that a vaccine is safe and effective.
Vaccine EUA Authorization
FDA may grant an EUA for a vaccine if it is reasonable to believe, based on the totality of the evidence, including evidence from adequate and well-controlled clinical trials, that:
- The product may be effective in preventing COVID-19.
- The known and potential benefits of the use of the vaccine outweigh the known and potential risks of the product.
- There is no adequate, approved and available alternative to the product for preventing COVID-19.
FDA expects that products manufactured under an EUA will be manufactured in compliance with good manufacturing practices.
Vaccine Expedited Programs
FDA has multiple programs intended to facilitate and speed the review and approval of new therapies for the treatment of serious or life-threatening conditions: Fast Track designation, Breakthrough Therapy designation, Accelerated Approval and Priority Review designation. Developers must demonstrate that they meet the basic regulatory criteria to apply for these programs. A serious disease or condition is “associated with morbidity that has substantial impact on day-to-day functioning” (see 21 CFR § 312.300(b)(1)). A life-threatening condition is a disease or condition “where the likelihood of death is high unless the course of the disease is interrupted . . . and . . . with potentially fatal outcomes, where the end point of clinical trial analysis is survival” (see 21 CFR 312.81(a)). For all of these expedited programs, the applicant must also demonstrate the requisite level of evidence to support the safety and effectiveness of the product at a population level.
FDA has previously granted expedited program designations to therapies for public health emergencies. For example, in December 2019, FDA announced its approval of the first vaccine for the prevention of Ebola virus disease. FDA had granted the applicant Priority Review and Breakthrough Therapy designations. Because of the public health emergency, FDA completed its safety and efficacy evaluation in less than six months and approved the vaccine. As another example, in January 2018, FDA granted Fast Track designation to a Zika virus vaccine in development.
During a public health emergency, a vaccine may receive Accelerated Approval under 21 CFR §§ 601.40 and 601.41 based on adequate, well-controlled clinical trials establishing an effect on a surrogate endpoint (i.e., biological indicators) that is reasonably likely to predict clinical benefit.
In the United States, the Biomedical Advanced Research and Development Authority of the US Department of Health and Human Services, the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health, global nonprofits and private companies are funding vaccine development. On February 25, 2020, the first clinical trial in the United States to evaluate an experimental treatment for COVID-19 began. This clinical trial, sponsored by NIAID and conducted at the University of Nebraska Medical Center, is “a randomized, controlled clinical trial to evaluate the safety and efficacy of the investigational antiviral remdesivir in hospitalized adults diagnosed with COVID-19.” FDA stated that, although “sponsors are usually expected to allow 30 days between submission and initiation of an initial IND protocol to allow for safety review, FDA has been using both pre-IND discussions and highly expedited initial review to allow such trials to begin as soon as possible.”
FDA has expressed a willingness to work with interested sponsors to help expedite the clinical trial process for COVID-19 treatments and products. In a global pandemic, FDA and other US agencies may coordinate with international agencies and review research conducted outside the United States to support approval, and the World Health Organization (WHO) plays a vital role in assessing the ethics of testing in human subjects under the circumstances. For example, in designing its current clinical trial, NIAID leveraged WHO consultations on developing clinical trials for patients with COVID-19 and information regarding study design from the clinical trials of remdesivir currently ongoing in China.
For any expedited clinical trials, developers are obligated to conduct post-marketing studies to verify the clinical benefit.
Medical Product Supply Chain
FDA indicated that it is monitoring how the coronavirus outbreak in China may affect medical product supply chains. Here is the status of key products as of FDA’s most recent update on February 27, 2020:
- Human Drugs: Manufacturers of approved human drugs must notify FDA of any anticipated supply disruptions (see 21 CFR § 314.81). To date, FDA has contacted more than 180 manufacturers of human drugs to ask them to evaluate their entire supply chain for ingredients and components sourced from China. FDA also independently identified about 20 non-critical drugs (i.e., drugs that can safely be withheld for a period of time) that solely source their active pharmaceutical ingredients or finished drug products from China. FDA contacted the manufacturers of these drugs to assess whether they face any drug shortage risks, but none have reported such a risk at this time.
- Biologics and Blood Products: Manufacturers of licensed biological products also must notify FDA of anticipated supply disruptions (see 21 CFR § 600.82). There are no shortages of biologics at this time, and FDA is not aware of any cellular or gene therapies for the US market that are manufactured in China.
- Medical Devices: There is no law requiring medical device manufacturers to report potential shortages or supply chain disruptions, or to otherwise respond to FDA requests for information about potential supply chain disruption. However, FDA has independently identified 62 manufacturers that produce essential medical devices, i.e., those that may be prone to shortage if there is a supply disruption, and is maintaining contact with them. There are currently no reported shortages of these manufacturers’ devices in the United States.
- Food: Currently, FDA is not aware of any evidence suggesting that COVID-19 can be transmitted by food or food packaging.
- Animal Drugs: FDA has identified 32 animal drug firms that source active pharmaceutical ingredients or finished drugs from China. There are no shortages at this time, but six of the firms have indicated supply chain disruptions could soon lead to shortages.
While the above assessments are focused on China, Dr. Hahn discussed four proposed initiatives in his testimony at the coronavirus hearing before the Senate Committee on Health, Education, Labor and Pensions (HELP Committee) on March 3, 2020, to mitigate or alleviate medical product shortages more broadly:
- Lengthening expiration dates of human drugs by giving FDA the authority to require applicants to evaluate, submit studies and label products with the longest possible expiration date to alleviate shortages
- Improving infrastructure through risk management plans by giving FDA the authority to require application holders of certain drugs to conduct periodic risk assessments to identify vulnerabilities in their supply chain and develop plans to mitigate such risks
- Improving infrastructure through improved data sharing and more accurate supply chain information by giving FDA the authority to require information to assess critical infrastructure, manufacturing quality and manufacturing capacity
- Establishing reporting requirements for medical device manufacturers, since, as noted, FDA currently does not have the same authorities for device shortages that it does for drugs and biologics.
The signed appropriations bill to provide emergency funding for the COVID-19 outbreak, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020, only provides FDA with funding for “the development of necessary medical countermeasures and vaccines, advanced manufacturing for medical products, the monitoring of medical product supply chains, and related administrative activities.” Congress did not grant FDA explicit authority—including enforcement authority—for the above proposals. The Senate HELP Committee is examining whether to extend these authorities to FDA, and stakeholders should provide comments to committee members.
FDA announced on March 10, 2020, that it is postponing its routine foreign inspections—including pre-approval inspections—through April. FDA will evaluate whether to conduct “for cause” inspections on a case-by-case basis. The agency indicated that the decision was based on a number of factors, including State Department Level 4 travel advisories that prohibit travel for federal employees, Centers for Disease Prevention and Control travel recommendations, entry and access restrictions in foreign countries, and Office of Personnel Management guidance.
FDA is implementing temporary measures to ensure product safety, such as:
- Denying entry of unsafe products into the United States
- Conducting additional physical examinations or product sampling at the borders in cooperation with US Customs and Border Protection
- Reviewing firms’ compliance histories
- Using information sharing with foreign governments based on existing mutual recognition or confidentiality agreements
- Requesting records “in advance of or in lieu of” onsite drug inspections.
FDA also has a risk-based screening tool, PREDICT, which assigns risk scores to focus physical examinations and sample collection. It remains to be seen if and how COVID-19 may affect FDA’s other enforcement and regulatory activities.
Several well-intentioned companies are attempting to develop innovative products to identify or treat COVID-19. FDA and the Federal Trade Commission (FTC) historically have monitored and taken fairly aggressive enforcement action against companies that they view as promoting fraudulent products during outbreak situations, i.e., products that claim to have benefits without approval. As of this writing, FDA and FTC have issued warning letters to seven companies accused of selling unapproved products for the prevention or treatment of COVID-19. FDA stated that it will continue to aggressively monitor the market for fraudulent COVID-19 prevention and treatment claims, and that it will use every authority at its disposal to protect consumers from bad actors. It is important for developers, including over-the-counter drug developers and developers of artificial intelligence-based diagnostics and patient assessments, to proactively engage with FDA to seek the appropriate approval for their products.

COVID-19 – Recent Legal Developments in Italy and Practical Implications
ARTICLE / CLIENT ALERT
COVID-19 – Recent Legal Developments in Italy and Practical Implications
March 12, 2020
Read time: 12 min
The Italian government is taking stringent measures to slow the spread of COVID-19. This Update offers up-to-the-minute insights into the current regulations governing individuals’ movement in Italy, work-related exceptions to those restrictions, and an explanation of other measures that could affect business operations.
The rapid spread of COVID-19 in Italy has induced the Italian government to take stringent measures aimed at slowing the spread of the virus to a rate which should gradually result in the country’s recovery from its current emergency situation.
Apart from specific sectors, the measures initially focused on relatively small geographic areas where the spread had begun. In light of the recent increase in number of people affected, new measures have been adopted to cover larger areas, most recently the whole Italian territory. These measures have a material practical impact on business activities carried out in Italy (not to mention the impact on the daily lives of the individuals concerned).
In particular, on 8 March 2020, a decree of the President of the Council of Ministers was issued to supplement and corroborate the previously enacted regulations to address the COVID-19 emergency.
The main impact of the latest measures set forth under the decree is on individuals’ movement until 3 April 2020.
The temporary restrictions on individuals’ movement under the decree were initially meant to apply to certain geographical areas (located in the north of the country) which had been identified as those with the highest rate of coronavirus infections (restricted areas). However, as a result of the increasing number of people affected by the virus, the President of the Council of Ministers issued a new decree on 9 March 2020, effective 10 March 2020 (supplementary decree), for the purpose of extending such restrictions to the whole Italian territory.
After issuance of such decrees imposing restrictions on individuals’ movements, another decree of the President of the Council of Ministers was issued on 11 March 2020, effective 12 March 2020, dictating the temporary shutdown of retailing activities in the Italian territory (with certain exceptions) until 25 March 2020.
Read on for an update on certain key issues relating to how local operations may be affected based on the applicable regulations, as enacted, amended and superseded by such decrees and in force today. This regulatory framework may constantly change based on the outcome of the measures adopted thereby, so further updates will follow to provide a detailed and up-to-date overview of ongoing developments.
INDIVIDUALS’ MOVEMENT
Before issuance of the 8 March decree, temporary restrictions on individuals’ movement applied only to the areas (consisting of single municipalities) where the virus had originated. The decree extended the geographic area of these restrictions, by dictating that, until 3 April 2020, individuals were not in principle allowed to leave or enter into, or even move, within the restricted areas, which were identified as those with the highest rate of coronavirus infections. Under the decree, the restricted areas were massively increased and included the whole Lombardy region, including Milan, and other areas which included other prominent cities, such as Venice, Padoa and Treviso.
Now, pursuant to the 9 March supplementary decree, the temporary restrictions on individuals’ movements have been extended to the whole Italian territory, until 3 April 2020. As a result, no individual currently is allowed any movement from, to or within the whole Italian territory, except in case of well-grounded work-related reasons, status of necessity or health-related reasons.
It was not initially clear, and to which extent, movement within the same municipality would be subject to these restrictions, while it was quite certain that transfers from one municipality to another in the Italian territory would fall within the decree’s scope of application. After the publication of the relevant guidelines by the Civil Protection Department, the restrictions seem to apply to any movement, including within the same municipality.
It should be noted that at the last minute, the draft of the decree (at that time meant to apply only to the restricted areas) was amended to specify that the restrictions would not apply to an individual’s return to her place of residence. This amendment was intended to allow people staying outside their places of residence at the time of the issuance of the decree to be able to return home. This stipulation now applies to the whole Italian territory, so individuals remain entitled to return home at any time from wherever they currently are.
Due to the “well-grounded work-related reasons” exception, employees required to move into, from or within the Italian territory for actual business reasons should not be prevented from doing so, to the extent that they can prove actual work related reasons.
Neither the decree nor the supplementary decree provides any specific examples of what would constitute “well-grounded work-related reasons”. A common sense interpretation would suggest that any movement for a genuine, material business reason should be sufficient to invoke the exception to the movement restrictions.
This interpretation seems to be confirmed by, inter alia, the following circumstances:
- Originally, the draft of the 8 March decree made reference to “non-deferrable work-related reasons”, while in the final text, “non-deferrable” has been replaced with “well-grounded” to mitigate the requirement.
- Certain supplementary regulations issued on 8 March 2020 by the Civil Protection Department by means of order no. 646 to clarify the scope of the decree specified that movement for “work-related reasons” are allowed in the whole country (omitting any reference to “well-grounded” as a prerogative).
In any event, it is plausible to maintain that, as confirmed by several government officials, employees will not be prevented from going to and from their workplace to perform their daily duties as usual. In the press release issued in connection with the adoption of the supplementary decree, the Italian Prime Minister indicated that public transportation services would not be suspended for the time being, in order to enable individuals to go to work (although following issuance of the 11 March decree, it now appears that the services may be subject to downsizing, as specified below).
Individuals may self-certify the work-related exception (“under penalty of perjury”). In case of employees, it would be advisable from a practical perspective to have the employer issue a certification letter to be shown to the officials in case of an inspection.
Untrue statements may result in criminal liabilities, even if identified by the authorities at a later stage (and at a time when the restrictive measures are no longer in place), which would be added to the liabilities arising from the violation of the restrictions imposed by the 8 March decree and the related supplementary decree.
The work-related exception (as well as any other exception) would not apply to individuals subject to quarantine or who test positive for COVID-19 and are prohibited from leaving their houses and places of residence.
On 8 March 2020, the Ministry of the Foreign Affairs issued an explanatory note to specify that the exception for “well-grounded work-related reasons” also applies to individuals travelling to or from a foreign country, to the extent such reasons exist, and therefore can be certified by the relevant individuals in case of inspection. Although this explanatory note was issued when the restrictions applied only to the restricted areas, in principle it indicates that an individual should be allowed to enter into the Italian territory from abroad or leave the Italian territory to travel abroad (unless such individual is banned from all movement due to other circumstances, as outlined previously).
Another issue to be taken into account relates to the potential overlap of regulations enacted at different local levels. Local governmental entities have enacted, and may continue to enact, supplementary regulations to prevent spread of the coronavirus in their territories. These local regulations may result in additional restrictions or difficulties in the interpretation of the actual measures applicable at the local level.
For instance, on 8 March 2020, when the decree had just been issued and applied only to the restricted areas, the Lazio region (which includes the city of Rome) issued an order that required individuals from the restricted areas who had entered into the Lazio territories in the previous 14 days, or who otherwise entered into such territories thereafter, to report their presence to the local authorities and, most importantly, to remain in their domicile, avoid any transfer or travel, and remain available for inspection by the authorities. Such order was amended on 9 March 2020 to set forth certain exceptions to such restrictions. Pursuant to the latest amendment, the restrictions set forth by the Lazio region no longer apply in case of, inter alia, movements into Lazio due to well-grounded work-related reasons. Because the supplementary decree essentially removed any difference between the restricted areas and the rest of the Italian territory, it seemed reasonable to believe that such order was no longer applicable after the extension of the restrictions to the whole Italian territory, but no express abrogation has yet been enacted and the Lazio region still seems to require individuals arriving from other regions to report their presence.
In any event, due to the potential overlap of regulations at different levels, any individual planning to move within the Italian territory under an exception should carefully assess what additional restrictions or burdens, if any, might be triggered in the place of destination upon entry, in addition to the general rules for movement under the decree itself.
Whether individuals leaving Italy for a foreign country may be subject to restrictions in the country of destination is an issue that should be assessed on a case-by-case basis, since the assessment will depend on the legal framework applicable in the country of destination.
OTHER MEASURES AFFECTING WORK ACTIVITIES UNDER THE 8 MARCH AND 9 MARCH DECREES
The 8 March decree sets forth other precautionary measures to reduce circumstances which may favour the spread of the coronavirus within the Italian territory.
These measures include the following:
- Public events (including, for instance, conferences) are suspended, regardless of whether they were to be held in public or private locations.
- Persons running commercial businesses are strongly advised to adopt measures to avoid crowding in their spaces and ensure a minimum distance of one meter among any visitors. Persons running restaurants and bars are obligated to adopt such measures.
- Employers are encouraged to facilitate employee use of available holiday leave.
- Implementation of “smart-working” (a more flexible form of working provided for by Italian law, which includes working remote) is also recommended during the emergency (with some flexibility in respect of the ordinary set of regulations applicable to smart-working).
The 9 March supplementary decree also added a new restrictive measure that forbids crowding.
MOVEMENT OF GOODS
Current regulations addressing COVID-19, including the 8 March decree and the supplementary decree, do not contain any reference to the movement of goods to, from or within Italy.
The aforementioned Civil Protection Department order confirmed that the restrictions set out in the 8 March decree do not apply to transit or transportation of goods or supply chains in the restricted areas. As such decree now applies to the whole Italian territory, such interpretation currently applies to any transit or movement of goods in Italy.
The Ministry of Foreign Affairs explanatory note, issued immediately after the 8 March decree (whose restrictions to movements were then applicable only to the restricted areas) and also published by the Ministry of Transportation and the Ministry of the Economic Development, provided a consistent interpretation, whereby no restriction would apply to any movement of goods from or to the restricted areas. The note also stated that employees dedicated to transportation of goods in the restricted areas would be deemed to benefit from the exception of the “well-grounded work-related reasons” which allows them to move within, into and from the restricted areas in connection with such transportation, to the extent required to collect and deliver goods, and would be entitled to self-certify such exception in case of any inquiry or inspection. Again, because the restrictions on individuals’ movements have been extended to the whole Italian territory under the supplementary decree, such interpretation should apply to any movement in the Italian territory.
The work-related exception does not apply to those employees subject to quarantine or found to have the virus, who are totally banned from any movement under the 8 March decree.
The regulations in comment, therefore, do not seem to restrict the export or import of goods in or from the Italian territory. Similarly, employees dedicated to the transportation of imported or exported goods from any foreign countries to the Italian territory, or from the Italian territory to any foreign countries, should benefit from the exception to the restrictions to individuals’ movements, to the extent their activity is required for the collection or delivery of goods.
Whether the shipment of goods from Italy into other countries is prevented by restrictions set out in such countries as a result of the coronavirus spread must be assessed on a case-by-case basis.
TEMPORARY SHUTDOWNS
As a result of the request from local governmental entities (including the Lombardy region) to increase the temporary measures aimed at reducing the increase of the coronavirus spread, the Government has issued the 11 March decree which, among other measures, has imposed the temporary shutdown in the Italian territory, until 25 March 2020, of:
- Any retailing activities, except for the sale of food and (other) essential retailing activities listed in an annex to such decree (which include, among others, sale of drugs and certain health-related products, sale of certain IT or other electrical components, online sales, etc.) and certain stores identified therein (i.e., pharmacies, para-pharmacies and sellers of newspapers or cigarettes).
- Certain activities providing services to individuals (including expressly hairdressers, barbers and similar shops) with certain exceptions (basically, laundering and funeral service providers).
- Bars, restaurants and similar businesses (with certain exceptions such as canteens at work places and food delivery services).
Manufacturing facilities and providers of professional services are not in principle subject to the temporary shutdown, but the decree contains certain recommendations, which include: (i) maximization of the use of “smart-working” solutions, (ii) maximization of the use by employees of available holiday leaves, (iii) shutdown of divisions that are not essential to the manufacturing (which recommendation seems to be limited to the manufacturing facilities, although the decree does not expressly make any differentiation), (iv) adoption of safety protocols, including to the extent possible ensuring the minimum distance of one meter among the relevant individuals, (v) sanitization of premises, (vi) limited to the manufacturing facilities, limitation of internal movements and rationalization of accesses thereto.
Essential services such as banking, financial and insurance services, and activities in the agricultural sectors (inclusive of the entire supply chains) will be guaranteed.

HSA Eligibility Not Disrupted by COVID-19 (Novel Coronavirus) Testing and Treatment
ARTICLE / CLIENT ALERT
HSA Eligibility Not Disrupted by COVID-19 (Novel Coronavirus) Testing and Treatment
March 11, 2020
Read time: 4 min
A new IRS notice will allow individuals to receive testing and care for COVID-19 without jeopardizing their ability to contribute to a health savings account (HSA). The IRS issued the notice due to the public health threat posed by COVID-19, and the stated need to eliminate potential administrative and financial barriers to testing for and treatment of COVID-19.
On March 11, 2020, the Internal Revenue Service (IRS) issued Notice 2020-15. Under the Notice, individuals covered by a high-deductible health plan (HDHP) may receive benefits associated with testing for and treatment of COVID-19—commonly referred to as Novel Coronavirus—without a deductible, or with a deductible below the minimum deductible for a HDHP, prior to the individual meeting the minimum deductible without disqualifying them from making or receiving HSA contributions. This change will allow individuals to pursue testing and treatment for COVID-19 without fear of jeopardizing their ability to contribute or receive contributions to their HSA for necessary care that may otherwise be more difficult to afford.
Many employers have asked whether the Notice extends to the provision of telemedicine and other forms of virtual care. As of the date this article was published, the IRS has not specifically stated whether the Notice grants any relief from the HSA rules for the provision of telemedicine at no cost to individuals enrolled in HDHPs. However, to the extent any telemedicine services are provided for the testing or treatment of COVID-19 as described in the Notice, the relief in the Notice should apply. Telemedicine services for other forms of treatment or care outside of and not related to COVID-19 would not be covered by the Notice.
The IRS announcement comes on the heels of announcements by several states, including, for example, California, New York, Maryland and Washington, mandating that insured health plans provide without cost-sharing certain medically necessary screening and testing (and, in certain cases, care) for COVID-19. These state mandates apply only to insured health plans. Some health insurers have already announced their intention to comply with these mandates. Self-insured group health plans are subject to Federal law under the Employee Retirement Income Security Act of 1974 (ERISA), which generally preempts state law as applied to self-insured group health plans. Many employers with self-insured group health plans, however, have sought ways to expand health plan coverage in line with the state guidance, and the Notice provides a way for them to do so.
HSAs allow eligible individuals to use pre-tax dollars to pay for eligible health care expenses. One requirement to participate in an HSA is that an individual be covered under a HDHP and have no “disqualifying health coverage.” As a general rule, any benefits covered under the HDHP before the minimum deductible is satisfied constitute disqualifying health coverage. A limited exception exists for preventive care that allows coverage of certain services, procedures and medications to be covered by the HDHP before a participant meets their deductible without affecting the individual’s ability to contribute to an HSA. This exception was recently expanded by the IRS to include certain medical expenses that treat an existing chronic condition but also prevent exacerbation of the condition and/or a future secondary condition (see our previous On the Subject here). The Notice is a further expansion and liberalization of the rules in light of the public health threat posed by COVID-19.

Privacy, HIPAA, Security and GDPR – COVID-19 Considerations
ARTICLE
Privacy, HIPAA, Security and GDPR – COVID-19 Considerations
March 2020
Read time: 1 min